In the absence of a submission from the holder of the marketing authorisation, vorapaxar (Zontivity®) cannot be endorsed for use within NHS Wales co-administered with acetylsalicylic acid and, where appropriate, clopidogrel, for the reduction of atherothrombotic events in adult patients with a history of myocardial infarction (MI); or symptomatic peripheral arterial disease (PAD). This product is currently not marketed in the UK.